Table 3.

Key findings

	Epilepsy treatment provided in UPF	Cost	Cost‐effectiveness (WHO guidelines)	Disease burden averted	Financial risk protection
Scenario 1	First‐line AEDs	High (approximately $220–$255 million per year through year 5,then $160–$185 million per year)	Very cost‐effective	High and somewhat progressive	Low or none
Scenario 2	First‐ and second‐line AEDs	High (slightly higher than in scenario 1)	Very cost‐effective	High (slightly higher than in scenario 1 and similarly progressive)	High and very progressive
Scenario 3	First‐ and second‐line AEDs and surgery	Extremely high (extremely high through year 5, then slightly higher than in scenario 2)	Very cost‐effective	High (slightly higher than in scenario 2 and similarly progressive)	High (slightly higher than in scenario 3, but less progressive)